Screener Summaries Updates Institutions Sign In More Updates › Financing › DYN Financing · Jun 8, 2026
Dyne Therapeutics held its 2026 Annual Meeting of Stockholders on June 5, 2026 DYN Dyne Therapeutics, Inc.
Dyne Therapeutics held its 2026 Annual Meeting of Stockholders on June 5, 2026. Stockholders approved an amendment to increase the number of authorized shares of common stock from 200 million to 400 million shares, as well as an amendment providing for officer exculpation.
More from Dyne Therapeutics, Inc. Reports Q3 net loss of $1.06 per share as cash position stands at $1.134 billion Nov 5, 2026 Dyne Therapeutics reports sustained functional improvement with zeleciment basivarsen in myotonic dystrophy type 1 trial Sep 29, 2026 Dyne Therapeutics reported a net loss of $178.6 million, or $1.08 per share, for the quarter ended June 30, 2026… Jul 29, 2026 Dyne Therapeutics, Inc. announced the pricing of an upsized underwritten public offering of 18,300,000 shares of… Jul 22, 2026 Dyne Therapeutics, Inc. announced that the FDA has accepted for review its biologics license application (BLA) for… Jul 20, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
